<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688493</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00001</org_study_id>
    <nct_id>NCT00688493</nct_id>
  </id_info>
  <brief_title>Effects of Single Oral Dose Dapagliflozin QT Study</brief_title>
  <official_title>A Double-blind, Randomized, Four-period Crossover Study to Assess the Effects of Single Oral Dose Dapagliflozin Administration on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Age 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine the effect of dapagliflozin on electronic
      measures of heart beats in healthy males
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electronic measures of heart beats</measure>
    <time_frame>ECGs (electronic measures of the heart) are taken at scheduled times during the 3 days after receiving each dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of dapagliflozin following single 20 mg and 150 mg doses in healthy volunteers</measure>
    <time_frame>At scheduled times during the 3 day periods following dosing during each of the 4 study periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of dapagliflozin</measure>
    <time_frame>Screening through completion of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>20 mg single dose of dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg dapagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg single dose of dapagliflozin2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg dapagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg single dose of moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>3 x 50 mg tablets, single oral dose</description>
    <arm_group_label>20 mg single dose of dapagliflozin</arm_group_label>
    <arm_group_label>150 mg single dose of dapagliflozin2</arm_group_label>
    <arm_group_label>400 mg single dose of moxifloxacin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>2 x 10 mg capsules, single oral dose</description>
    <arm_group_label>20 mg single dose of dapagliflozin</arm_group_label>
    <arm_group_label>150 mg single dose of dapagliflozin2</arm_group_label>
    <arm_group_label>400 mg single dose of moxifloxacin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Overencapsulated 400 mg capsule, single oral dose</description>
    <arm_group_label>20 mg single dose of dapagliflozin</arm_group_label>
    <arm_group_label>150 mg single dose of dapagliflozin2</arm_group_label>
    <arm_group_label>400 mg single dose of moxifloxacin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Avelox™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match moxifloxacin and dapagliflozin</intervention_name>
    <description>Overencapsulated 400 mg capsule, single oral dose</description>
    <arm_group_label>20 mg single dose of dapagliflozin</arm_group_label>
    <arm_group_label>150 mg single dose of dapagliflozin2</arm_group_label>
    <arm_group_label>400 mg single dose of moxifloxacin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males age 18 to 45 years of age, who are not currently taking any medications

          -  Normal screening results including a physical examination, laboratory tests, heart
             rate, blood pressure, and ECG (electronic measure of the heart)

        Exclusion Criteria:

          -  No personal or family history of significant heart problems

          -  No use of over the counter medications within 7 days of the study

          -  No use of prescription medicaiton within 1 month of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Carlson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Goldwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QT</keyword>
  <keyword>Healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

